PMID: 6020009Apr 1, 1967Paper

Cytotoxic potential of stimulated human lymphocytes

The Journal of Experimental Medicine
G Holm, P Perlmann

Abstract

Viable and immunologically competent lymphocytes from unsensitized donors damage allogeneic tissue culture cells in the presence of phytohemagglutinin (PHA). This cytotoxicity is specific since syngeneic tissue culture cells are not at all or only slightly damaged under similar experimental conditions. In this investigation, the relation between the stimulation of human lymphocytes and their cytotoxicity was studied. Chang cells (human liver) served as target cells in all experiments. Cell damage was quantitated by measuring the release of isotope from target cells labeled with chromate-(51)Cr. The cytotoxicity of the lymphocytes was dependent on the concentration of PHA in the incubation medium. Cell damage was maximal at concentrations of 4-8 microl PHA/ml. Higher concentrations were inhibitory although aggregation was increased and no injury of the lymphocytes was noted. Stimulation of DNA and RNA synthesis in PHA-treated lymphocytes each followed dose response curves which were similar to that of cytotoxicity. In order to establish whether stimulation without mixed aggregation of lymphocytes and target cells would suffice for cytotoxicity, a series of nonagglutinating stimulants were investigated. Lymphocytes pretreated wit...Continue Reading

References

Oct 1, 1966·The Journal of Experimental Medicine·G Harris, R J Littleton
Jan 18, 1966·Biochimica Et Biophysica Acta·G C Mueller, M L Mahieu
Mar 23, 1963·Lancet·G PEARMAINP H FITZGERALD
Aug 3, 1963·British Medical Journal·L BRENT, P B MEDAWAR
Nov 23, 1963·Lancet·D C COWLINGE DAVIDSON
Feb 15, 1964·Lancet·N R LING, E M HUSBAND
Feb 29, 1964·Lancet·A S COULSON, D G CHALMERS
Jul 1, 1965·British Journal of Haematology·N R LINGN WILLIAMSON

❮ Previous
Next ❯

Citations

Jan 1, 1972·Journal of Surgical Oncology·G E Moore
Mar 1, 1989·The British Veterinary Journal·C R Mackay, I R Mackay
Sep 1, 1970·Cellular Immunology·P Perlmann, H Perlmann
Jan 1, 1978·Journal of Immunological Methods·G Huges-LawT H The
Mar 1, 1968·Proceedings of the National Academy of Sciences of the United States of America·B Bennett, B R Bloom
Jun 1, 1972·Proceedings of the National Academy of Sciences of the United States of America·D P StitesH H Fudenberg
Oct 1, 1968·The Journal of Experimental Medicine·E R Hurd, M Ziff
Dec 1, 1968·The Journal of Experimental Medicine·N H Ruddle, B H Waksman
Apr 1, 1971·The Journal of Experimental Medicine·I R CohenM Feldman
May 1, 1976·The Journal of Experimental Medicine·L ShouR A Good
Jan 1, 1972·Transplantation Reviews·I C MacLennan
Feb 13, 1970·Annals of the New York Academy of Sciences·B R Bloom, B Bennett
May 1, 1975·The Journal of Clinical Investigation·J R WandsK J Isselbacher
Jan 1, 1978·Journal of Immunopharmacology·A Winkelstein, J A Brizzi
Feb 1, 1983·International Journal of Oral Surgery·M MalmströmF Fyhrquist
Oct 1, 1981·Scandinavian Journal of Immunology·C L YueY Horiuchi
Jul 25, 1973·Nature: New Biology·R Liske
Mar 28, 1973·Nature: New Biology·A H GreenbergI M Roitt
Jul 15, 1975·International Journal of Cancer. Journal International Du Cancer·P HerseyD S Nelson
Jan 1, 1967·Scandinavian Journal of Haematology·G Holm

❮ Previous
Next ❯

Related Concepts

Related Feeds

Allogenic & Autologous Therapies

Allogenic therapies are generated in large batches from unrelated donor tissues such as bone marrow. In contrast, autologous therapies are manufactures as a single lot from the patient being treated. Here is the latest research on allogenic and autologous therapies.